AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 17367953 — intervention group
Group type: EXPERIMENTAL
Intervention: Manual-guided group behavioral therapies (Cognitive Behavioral Therapy or Twelve Step Facilitation)
Number of subjects: 78
Study 16276167 — intervention group
Group type: EXPERIMENTAL
Intervention: Noninvasive ventilation (NIV) for > or = 8 hrs a day in the first 48 hrs
Number of subjects: 97
Study 16276167 — intervention group
Group type: COMPARATOR
Intervention: Standard medical therapy (SMT)
Number of subjects: 97
Study 16276167 — intervention group
Group type: EXPERIMENTAL
Intervention: Noninvasive ventilation (NIV)
Number of subjects: 97
Study 12003439 — intervention group
Group type: EXPERIMENTAL
Intervention: Elk velvet antler (2 capsules, 215 mg each)
Number of subjects: 40
Study 12003439 — intervention group
Group type: EXPERIMENTAL
Intervention: Elk velvet antler (4 capsules, 215 mg each)
Number of subjects: 40
Study 12003439 — intervention group
Group type: EXPERIMENTAL
Intervention: Elk velvet antler (6 capsules, 215 mg each)
Number of subjects: 40
Study 12003439 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study 9705684 — intervention group
Group type: EXPERIMENTAL
Intervention: Eptifibatide
Number of subjects: 10948
Study 9705684 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10948
Study 7614523 — intervention group
Group type: EXPERIMENTAL
Intervention: Naproxen, 500 mg twice daily
Number of subjects: 99
Study 7614523 — intervention group
Group type: COMPARATOR
Intervention: Nabumetone, 1,000 mg once daily
Number of subjects: 99
Study 2203262 — intervention group
Group type: EXPERIMENTAL
Intervention: Naproxen 500 mg in the morning and 250 mg in the evening
Number of subjects: 10
Study 2203262 — intervention group
Group type: EXPERIMENTAL
Intervention: Sulindac 200 mg twice a day
Number of subjects: 10
Study 2203262 — intervention group
Group type: EXPERIMENTAL
Intervention: Both drugs
Number of subjects: 10
Study 1194473 — intervention group
Group type: EXPERIMENTAL
Intervention: Transactional analysis program (O.H. Close School)
Number of subjects: 983
Study 1194473 — intervention group
Group type: EXPERIMENTAL
Intervention: Behavior modification program (Karl Holton School)
Number of subjects: 983
Study 1194473 — intervention group
Group type: COMPARATOR
Intervention: Both programs
Number of subjects: 983
Study 31948665 — intervention group
Group type: EXPERIMENTAL
Intervention: Hybrid group (routine electrophysiological confirmation and additional catheter ablation after totally thoracoscopic ablation)
Number of subjects: 45
Study 31948665 — intervention group
Group type: COMPARATOR
Intervention: TTA group (no routine electrophysiological confirmation)
Number of subjects: 45
Study 31948665 — intervention group
Group type: COMPARATOR
Intervention: TTA group
Number of subjects: 45
Study 31948665 — intervention group
Group type: EXPERIMENTAL
Intervention: Hybrid group
Number of subjects: 45
Study 30630649 — intervention group
Group type: EXPERIMENTAL
Intervention: Carotid endarterectomy (CEA)
Number of subjects: 1181
Study 30630649 — intervention group
Group type: EXPERIMENTAL
Intervention: Carotid artery stenting (CAS)
Number of subjects: 1181
Study 30630649 — intervention group
Group type: COMPARATOR
Intervention: Pooled CEA and CAS
Number of subjects: 1181
Study 29231431 — intervention group
Group type: EXPERIMENTAL
Intervention: Micro-invasive embedding combined with montelukast sodium
Number of subjects: 240
Study 29231431 — intervention group
Group type: COMPARATOR
Intervention: Montelukast sodium (5 mg once daily for 3 months)
Number of subjects: 240
Study 25169119 — intervention group
Group type: EXPERIMENTAL
Intervention: Neoadjuvant chemoradiotherapy (CRT) - cisplatin and 5-fluorouracil with 45 Gy of concurrent radiotherapy
Number of subjects: 116
Study 25169119 — intervention group
Group type: COMPARATOR
Intervention: Perioperative chemotherapy (PCT) - docetaxel, cisplatin, 5-FU
Number of subjects: 116
Study 25169119 — intervention group
Group type: EXPERIMENTAL
Intervention: Neoadjuvant chemoradiotherapy (CRT)
Number of subjects: 116
Study 25169119 — intervention group
Group type: COMPARATOR
Intervention: Perioperative chemotherapy (PCT)
Number of subjects: 116
Study 22774852 — intervention group
Group type: EXPERIMENTAL
Intervention: Retrieval practice (testing)
Number of subjects: 0
Study 22774852 — intervention group
Group type: COMPARATOR
Intervention: Subsequent restudy opportunity
Number of subjects: 0
Study 21493739 — intervention group
Group type: EXPERIMENTAL
Intervention: Warfarin (low-intensity monitored-dose, target INR 1.5 to 1.9)
Number of subjects: 174
Study 21493739 — intervention group
Group type: EXPERIMENTAL
Intervention: Warfarin
Number of subjects: 174
Study 21493739 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 174
Study 18218827 — intervention group
Group type: EXPERIMENTAL
Intervention: High-resistance exercise (HR group)
Number of subjects: 102
Study 18218827 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-resistance exercise (LR group)
Number of subjects: 102
Study 18218827 — intervention group
Group type: COMPARATOR
Intervention: Control group (no exercise)
Number of subjects: 102
Study 16763086 — intervention group
Group type: EXPERIMENTAL
Intervention: New antimicrobial and fluoride-releasing self-etching primer (Clearfil Protect Bond) used according to manufacturer's recommendations
Number of subjects: 120
Study 16763086 — intervention group
Group type: EXPERIMENTAL
Intervention: New antimicrobial and fluoride-releasing self-etching primer (Clearfil Protect Bond) used without prior etching
Number of subjects: 120
Study 16763086 — intervention group
Group type: COMPARATOR
Intervention: Conventional bonding procedure (etching, Transbond XT)
Number of subjects: 120
Study 14690568 — intervention group
Group type: EXPERIMENTAL
Intervention: Gemcitabine 1000 mg/m2 + NS 100 ml or 200 ml (Group A)
Number of subjects: 124
Study 14690568 — intervention group
Group type: EXPERIMENTAL
Intervention: Gemcitabine 1000 mg/m2 + Cisplatin 30 mg/m2 (Group B)
Number of subjects: 124
Study 14690568 — intervention group
Group type: COMPARATOR
Intervention: Imported Gemzar + Cisplatin 30 mg/m2 (Group C)
Number of subjects: 124
Study 14690568 — intervention group
Group type: EXPERIMENTAL
Intervention: Cisplatin 30 mg/m2 (Group B)
Number of subjects: 124
Study 14690568 — intervention group
Group type: EXPERIMENTAL
Intervention: Hematological toxicity (Groups B and C)
Number of subjects: 124
Study 10768309 — intervention group
Group type: EXPERIMENTAL
Intervention: Topiramate (TPM) at a mean dosage of 29 mg/kg/day, maximum dosage of 50 mg/kg/day, for a mean duration of 18 months.
Number of subjects: 11
Study 8614073 — intervention group
Group type: EXPERIMENTAL
Intervention: Cryopreserved cultured epidermal allografts (CEAs)
Number of subjects: 16
Study 8614073 — intervention group
Group type: COMPARATOR
Intervention: Control treatment
Number of subjects: 16
Study 1293910 — intervention group
Group type: EXPERIMENTAL
Intervention: VAD regimen (vincristine, doxorubicin, dexamethasone)
Number of subjects: 56
Study 1293910 — intervention group
Group type: COMPARATOR
Intervention: Dexamethasone (D)
Number of subjects: 56
Study 6376485 — intervention group
Group type: EXPERIMENTAL
Intervention: Isocarboxazid (40-50 mg/day)
Number of subjects: 0
Study 31218759 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral therapy (CBT)
Number of subjects: 66
Study 31218759 — intervention group
Group type: EXPERIMENTAL
Intervention: Observer-based rating scale for skills assessment (SAPH)
Number of subjects: 66
Study 28941006 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 μg/kg palonosetron
Number of subjects: 565
Study 28941006 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 μg/kg palonosetron
Number of subjects: 565
Study 28941006 — intervention group
Group type: COMPARATOR
Intervention: 3 × 150 μg/kg ondansetron
Number of subjects: 565
Study 27163805 — intervention group
Group type: EXPERIMENTAL
Intervention: Bapineuzumab
Number of subjects: 0
Study 27163805 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 24447683 — intervention group
Group type: EXPERIMENTAL
Intervention: Sitagliptin
Number of subjects: 120
Study 24447683 — intervention group
Group type: COMPARATOR
Intervention: α-glucosidase inhibitor (αGI)
Number of subjects: 120
Study 22316445 — intervention group
Group type: EXPERIMENTAL
Intervention: Tai chi
Number of subjects: 195
Study 20395612 — intervention group
Group type: EXPERIMENTAL
Intervention: Anodal tDCS (1 mA for 20 minutes)
Number of subjects: 10
Study 20395612 — intervention group
Group type: COMPARATOR
Intervention: Sham tDCS (for 20 minutes)
Number of subjects: 10
Study 16394780 — intervention group
Group type: EXPERIMENTAL
Intervention: Ventilatory strategy
Number of subjects: 0
Study 16394780 — intervention group
Group type: COMPARATOR
Intervention: Control group participants
Number of subjects: 0
Study 12679451 — intervention group
Group type: EXPERIMENTAL
Intervention: Total estradiol
Number of subjects: 845
Study 12679451 — intervention group
Group type: EXPERIMENTAL
Intervention: Bioavailable estradiol
Number of subjects: 845
Study 12679451 — intervention group
Group type: EXPERIMENTAL
Intervention: Bioavailable testosterone
Number of subjects: 845
Study 12679451 — intervention group
Group type: EXPERIMENTAL
Intervention: Bioavailable estradiol (after adjusting for body mass index and WHR)
Number of subjects: 845
Study 10720847 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic procedures (nephrectomy, renal cyst marsupialization, varix ligation)
Number of subjects: 145
Study 10720847 — intervention group
Group type: COMPARATOR
Intervention: Open unilateral nephrectomy
Number of subjects: 145
Study 10720847 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic procedures (including ESWL and minor procedures)
Number of subjects: 145
Study 9113940 — intervention group
Group type: EXPERIMENTAL
Intervention: Salmeterol (50 microg once daily)
Number of subjects: 14
Study 9113940 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 14
Study 1410072 — intervention group
Group type: EXPERIMENTAL
Intervention: Broad spectrum fluorescent light
Number of subjects: 11
Study 1410072 — intervention group
Group type: COMPARATOR
Intervention: Cool white light
Number of subjects: 11
Study 3890504 — intervention group
Group type: EXPERIMENTAL
Intervention: Cimetidine, 300 mg orally every 6 hours
Number of subjects: 11
Study 3890504 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 11
Study 30044959 — intervention group
Group type: EXPERIMENTAL
Intervention: Allogeneic umbilical cord-derived mesenchymal stem cells (MSCs) at doses of 1 × 10^6 cells/kg, 2 × 10^6 cells/kg, and 3 × 10^6 cells/kg
Number of subjects: 15
Study 30044959 — intervention group
Group type: EXPERIMENTAL
Intervention: Allogeneic umbilical cord-derived mesenchymal stem cells (MSCs)
Number of subjects: 15
Study 30044959 — intervention group
Group type: COMPARATOR
Intervention: Historical case-matched comparison group
Number of subjects: 15
Study 26656140 — intervention group
Group type: EXPERIMENTAL
Intervention: Model including self-reported socioeconomic, health status, and psychosocial characteristics
Number of subjects: 1004
Study 26656140 — intervention group
Group type: COMPARATOR
Intervention: Model incorporating only clinical and demographic factors
Number of subjects: 1004
Study 24553557 — intervention group
Group type: EXPERIMENTAL
Intervention: Brief alcohol interventions in Study 1
Number of subjects: 2089
Study 24553557 — intervention group
Group type: EXPERIMENTAL
Intervention: Brief alcohol interventions in Study 2
Number of subjects: 2089
Study 22289995 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose dexamethasone (HD-DXM) 40 mg/day for 4 consecutive days
Number of subjects: 25
Study 22289995 — intervention group
Group type: COMPARATOR
Intervention: Pretherapy patients
Number of subjects: 25
Study 22289995 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose dexamethasone (HD-DXM)
Number of subjects: 25
Study 20216531 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral treatment targeting parents' responses and children's coping (3 sessions)
Number of subjects: 200
Study 20216531 — intervention group
Group type: COMPARATOR
Intervention: Educational intervention (3 sessions)
Number of subjects: 200
Study 17353100 — intervention group
Group type: EXPERIMENTAL
Intervention: Concomitant (escape and avoidance) schedules of reinforcement
Number of subjects: 0
Study 17353100 — intervention group
Group type: COMPARATOR
Intervention: Other operant schedules (not specified)
Number of subjects: 0
Study 16555797 — intervention group
Group type: EXPERIMENTAL
Intervention: Nutrition labeling on restaurant menus
Number of subjects: 79
Study 16555797 — intervention group
Group type: EXPERIMENTAL
Intervention: Value size pricing
Number of subjects: 79
Study 16555797 — intervention group
Group type: EXPERIMENTAL
Intervention: Nutrition importance
Number of subjects: 79
Study 12570912 — intervention group
Group type: EXPERIMENTAL
Intervention: Growth hormone (GH) replacement therapy at an initial dose of 0.125 IU/Kg/week followed by 0.250 IU/Kg/week
Number of subjects: 165
Study 12570912 — intervention group
Group type: EXPERIMENTAL
Intervention: Growth hormone (GH) replacement therapy
Number of subjects: 165
Study 12570912 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 165
Study 12212211 — intervention group
Group type: EXPERIMENTAL
Intervention: Full-dose aprotinin (Group A, n = 10)
Number of subjects: 29
Study 12212211 — intervention group
Group type: EXPERIMENTAL
Intervention: Pump-prime-only aprotinin (Group B, n = 10)
Number of subjects: 29
Study 12212211 — intervention group
Group type: COMPARATOR
Intervention: Control group (Group C, n = 9)
Number of subjects: 29
Study 8808995 — intervention group
Group type: EXPERIMENTAL
Intervention: Water Exercisers (WE)
Number of subjects: 4
Study 8808995 — intervention group
Group type: EXPERIMENTAL
Intervention: Land Exercisers (LE)
Number of subjects: 4
Study 8808995 — intervention group
Group type: COMPARATOR
Intervention: Water Sitters (WS)
Number of subjects: 4
Study 8808995 — intervention group
Group type: COMPARATOR
Intervention: Land Sitters (LS)
Number of subjects: 4
Study 1390529 — intervention group
Group type: EXPERIMENTAL
Intervention: Subconjunctival injection of cefuroxime (125 mg)
Number of subjects: 20
Study 1390529 — intervention group
Group type: COMPARATOR
Intervention: Subconjunctival injection of both cefuroxime and Betnesol (betamethasone sodium phosphate 0.1%)
Number of subjects: 20
Study 4056964 — intervention group
Group type: EXPERIMENTAL
Intervention: Restrictive diets based on oral food challenge results
Number of subjects: 113
Study 4056964 — intervention group
Group type: COMPARATOR
Intervention: Double-blind placebo-controlled oral food challenges
Number of subjects: 113
Study 30392239 — intervention group
Group type: EXPERIMENTAL
Intervention: Anlotinib (12 mg daily from day 1 to 14 of a 21-day cycle)
Number of subjects: 24
Study 30392239 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study 26432285 — intervention group
Group type: EXPERIMENTAL
Intervention: EVAR with intraoperative sac embolization (group B)
Number of subjects: 107
Study 26432285 — intervention group
Group type: COMPARATOR
Intervention: Standard EVAR (group A)
Number of subjects: 107
Study 26432285 — intervention group
Group type: COMPARATOR
Intervention: Low risk group (group C)
Number of subjects: 107
Study 24560453 — intervention group
Group type: EXPERIMENTAL
Intervention: Full-spectrum endoscopy colonoscopy
Number of subjects: 185
Study 24560453 — intervention group
Group type: COMPARATOR
Intervention: Standard forward-viewing colonoscopy
Number of subjects: 185
Study 24560453 — intervention group
Group type: EXPERIMENTAL
Intervention: Both procedures
Number of subjects: 185
Study 22266154 — intervention group
Group type: EXPERIMENTAL
Intervention: CVT‐E002
Number of subjects: 293
Study 22266154 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 293
Study 20457982 — intervention group
Group type: COMPARATOR
Intervention: No initial treatment (control group)
Number of subjects: 118
Study 20457982 — intervention group
Group type: EXPERIMENTAL
Intervention: Exfoliation glaucoma (subgroup of patients)
Number of subjects: 118
Study 19081383 — intervention group
Group type: EXPERIMENTAL
Intervention: Donepezil (cholinesterase inhibitor)
Number of subjects: 0
Study 15939309 — intervention group
Group type: EXPERIMENTAL
Intervention: 1mg reproterol
Number of subjects: 19
Study 15939309 — intervention group
Group type: EXPERIMENTAL
Intervention: 2mg DSCG
Number of subjects: 19
Study 15939309 — intervention group
Group type: EXPERIMENTAL
Intervention: 1mg reproterol plus 2mg DSCG
Number of subjects: 19
Study 15939309 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 19
Study 12859089 — intervention group
Group type: EXPERIMENTAL
Intervention: OptiBond Solo (total-etch technique)
Number of subjects: 18
Study 12859089 — intervention group
Group type: EXPERIMENTAL
Intervention: Clearfil Liner Bond 2V (self-etching system)
Number of subjects: 18
Study 12859089 — intervention group
Group type: COMPARATOR
Intervention: No bonding material (control group)
Number of subjects: 18
Study 10527711 — intervention group
Group type: EXPERIMENTAL
Intervention: Liquid shark cartilage extract (7 ml)
Number of subjects: 29
Study 10527711 — intervention group
Group type: EXPERIMENTAL
Intervention: Liquid shark cartilage extract (21 ml)
Number of subjects: 29
Study 9112164 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.05% bromocriptine
Number of subjects: 24
Study 9112164 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.25% timolol
Number of subjects: 24
Study 9112164 — intervention group
Group type: COMPARATOR
Intervention: timolol
Number of subjects: 24
Study 9112164 — intervention group
Group type: EXPERIMENTAL
Intervention: timolol+bromocriptine
Number of subjects: 24
Study 9112164 — intervention group
Group type: COMPARATOR
Intervention: timolol+placebo
Number of subjects: 24
Study 9112164 — intervention group
Group type: COMPARATOR
Intervention: bromocriptine+placebo
Number of subjects: 24
Study 1683840 — intervention group
Group type: EXPERIMENTAL
Intervention: Cetirizine 10 mg
Number of subjects: 9
Study 1683840 — intervention group
Group type: EXPERIMENTAL
Intervention: Ebastine 10 mg
Number of subjects: 9
Study 7138750 — intervention group
Group type: EXPERIMENTAL
Intervention: Cimetidine (oral) for 2 months
Number of subjects: 8
Study 7138750 — intervention group
Group type: EXPERIMENTAL
Intervention: Cimetidine (intravenous infusion) for 48 hours
Number of subjects: 8
Study 7138750 — intervention group
Group type: COMPARATOR
Intervention: Placebo for 2 months
Number of subjects: 8
Study 29722800 — intervention group
Group type: COMPARATOR
Intervention: 1450 ppm fluoride toothpaste (Control group)
Number of subjects: 255
Study 29722800 — intervention group
Group type: EXPERIMENTAL
Intervention: 1450 ppm fluoride toothpaste plus 0.2% sodium fluoride mouth rinse
Number of subjects: 255
Study 29722800 — intervention group
Group type: EXPERIMENTAL
Intervention: 5000 ppm fluoride toothpaste
Number of subjects: 255
Study 28339993 — intervention group
Group type: EXPERIMENTAL
Intervention: Sucroferric oxyhydroxide (1.0-3.0 g/day)
Number of subjects: 84
Study 28339993 — intervention group
Group type: COMPARATOR
Intervention: Sevelamer (2.4-14.4 g/day)
Number of subjects: 84
Study 26625755 — intervention group
Group type: EXPERIMENTAL
Intervention: High onion group (HO; n=28) - 100-160 g/d of fresh yellow onion for 8 weeks
Number of subjects: 56
Study 26625755 — intervention group
Group type: COMPARATOR
Intervention: Low onion group (LO; n=28) - 30-40 g/d of small onion for 8 weeks
Number of subjects: 56
Study 23660274 — intervention group
Group type: EXPERIMENTAL
Intervention: RT‐IMRT
Number of subjects: 71
Study 23660274 — intervention group
Group type: COMPARATOR
Intervention: RP
Number of subjects: 71
Study 21856592 — intervention group
Group type: EXPERIMENTAL
Intervention: Colesevelam HCl (3.75 g/d)
Number of subjects: 696
Study 21856592 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 696
Study 18269662 — intervention group
Group type: EXPERIMENTAL
Intervention: SBG mouthwash (swallowed)
Number of subjects: 30
Study 18269662 — intervention group
Group type: EXPERIMENTAL
Intervention: SBG mouthwash (expectorated)
Number of subjects: 30
Study 18269662 — intervention group
Group type: COMPARATOR
Intervention: Water rinse (control)
Number of subjects: 30
Study 18269662 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups (SBG and control)
Number of subjects: 30
Study 17133147 — intervention group
Group type: EXPERIMENTAL
Intervention: Teen FreshStart Plus Buddy (TFS-B)
Number of subjects: 142
Study 17133147 — intervention group
Group type: COMPARATOR
Intervention: Usual Care (UC)
Number of subjects: 142
Study 17133147 — intervention group
Group type: EXPERIMENTAL
Intervention: Teen FreshStart (TFS)
Number of subjects: 142
Study 12969093 — intervention group
Group type: EXPERIMENTAL
Intervention: 200 mg ropivacaine HCl rectally in 20 mL hydroxypropyl methylcellulose gel
Number of subjects: 12
Study 12969093 — intervention group
Group type: EXPERIMENTAL
Intervention: 200 mg ropivacaine HCl rectally in 40 mL hydroxypropyl methylcellulose gel
Number of subjects: 12
Study 12969093 — intervention group
Group type: EXPERIMENTAL
Intervention: 200 mg ropivacaine HCl rectally in 60 mL hydroxypropyl methylcellulose gel
Number of subjects: 12
Study 12969093 — intervention group
Group type: EXPERIMENTAL
Intervention: 200 mg ropivacaine HCl rectally in 80 mL hydroxypropyl methylcellulose gel
Number of subjects: 12
Study 11121911 — intervention group
Group type: COMPARATOR
Intervention: 7-day triple therapy based on rabeprazole (20 mg b.d.), clarithromycin (250 mg t.d.s.), and amoxicillin (500 mg t.d.s.)
Number of subjects: 120
Study 11121911 — intervention group
Group type: EXPERIMENTAL
Intervention: 7-day triple therapy based on rabeprazole (20 mg b.d.), clarithromycin (250 mg t.d.s.), amoxicillin (500 mg t.d.s.) supplemented with a lyophilized and inactivated culture of Lactobacillus acidophilus (t.d.s.)
Number of subjects: 120
Study 9360784 — intervention group
Group type: EXPERIMENTAL
Intervention: GM-CSF primed PBSC
Number of subjects: 62
Study 9360784 — intervention group
Group type: EXPERIMENTAL
Intervention: GM-CSF mobilized BMSC
Number of subjects: 62
Study 9360784 — intervention group
Group type: EXPERIMENTAL
Intervention: G-CSF mobilized PBSC
Number of subjects: 62
Study 9360784 — intervention group
Group type: COMPARATOR
Intervention: PBSC
Number of subjects: 62
Study 9360784 — intervention group
Group type: COMPARATOR
Intervention: BMSC
Number of subjects: 62
Study 9360784 — intervention group
Group type: COMPARATOR
Intervention: G-CSF vs. GM-CSF
Number of subjects: 62
Study 1547767 — intervention group
Group type: EXPERIMENTAL
Intervention: Brand-name phenytoin (PHT)
Number of subjects: 10
Study 1547767 — intervention group
Group type: EXPERIMENTAL
Intervention: Generic phenytoin (PHT)
Number of subjects: 10
Study 3870624 — intervention group
Group type: EXPERIMENTAL
Intervention: Ticlopidine (500 mg)
Number of subjects: 0
Study 3870624 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 3870624 — intervention group
Group type: EXPERIMENTAL
Intervention: CU membrane (Gambro 120 M)
Number of subjects: 0